Trial Profile
A Phase 1 Study of Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 16 Apr 2020
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- 06 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 25 Jan 2013 Planned end date changed from 1 Aug 2012 to 1 Jul 2014 as reported by ClinicalTrials.gov.
- 06 Oct 2011 Planned End Date changed from 1 Jul 2011 to 1 Aug 2012 as reported by ClinicalTrials.gov.